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ABSTRACT
AM5(adrenomedullin5),anewlydescribedmemberoftheCGRP(calcitoningene-relatedpeptide)
family, is reported to play a role in normal cardiovascular physiology. The effects of AM5 in HF
(heart failure), however, have not been investigated. In the present study, we intravenously infused
two incremental doses of AM5 (10 and 100 ng/min per kg of body weight each for 90 min)
into eight sheep with pacing-induced HF. Compared with time-matched vehicle control infusions,
AM5 produced progressive and dose-dependent increases in left ventricular dP/dt(max) [LD (low
dose), +56 mmHg/s and HD (high dose), +152 mmHg/s] and cardiac output (+0.83 l/min and
+1.81l/min),togetherwithdecrementsincalculatedtotalperipheralresistance(−9.4mmHg/min
per litre and −14.7 mmHg/min per litre), mean arterial pressure (−2.8 mmHg and −8.4 mmHg)
and LAP (left atrial pressure; −2.6 mmHg and −5.6 mmHg) (all P<0.001). HD AM5 signiﬁcantly
raised PRA (plasma renin activity) (3.5-fold increment, P<0.001), whereas plasma aldosterone
levels were unchanged over the intra-infusion period and actually fell in the post-infusion period
(70% decrement, P<0.01), resulting in a marked decrease in the aldosterone/PRA ratio (P<0.01).
Despite falls in LAP, plasma atrial natriuretic peptide and B-type natriuretic peptide concentrations
were maintained relative to controls. AM5 infusion also induced signiﬁcant increases in urine
volume(HD2-foldincrement,P<0.05)andurinesodium(2.7-foldincrement,P<0.01),potassium
(1.7-foldincrement,P<0.05)andcreatinine(1.4-foldincrement,P<0.05)excretionandcreatinine
clearance (60% increment, P<0.05). In conclusion, AM5 has signiﬁcant haemodynamic, endocrine
andrenalactionsinexperimentalHFlikelytobeprotectiveandcompensatoryinthissetting.These
results suggest that AM5 may have potential as a therapeutic agent in human HF.
INTRODUCTION
The AMs (adrenomedullins) are a group of regulatory
peptides belonging to the CGRP (calcitonin gene-related
peptide) superfamily, all of which share a conserved
six-amino-acid intramolecular ring structure formed by
a single disulﬁde linkage and an amidated C-terminus
[1]. Although ﬁve members of the AM subfamily have
been identiﬁed in ﬁsh and named AM1–AM5 [2], until
recently only the ﬁrst two of these peptides were
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shown to have mammalian equivalents: AM [3] and
AM2 [4] (also known as intermedin). In mammals, AM
and AM2 are expressed throughout the central nervous
system and in multiple peripheral organs including the
heart, vasculature, kidneys and gastrointestinal tract
[5,6]. While both peptides are well recognized as being
multifunctional, their major role appears to be related to
BP (blood pressure)/volume homoeostasis, with actions
that include direct vasodilation [7], positive inotropism
[8,9] and diuresis and natriuresis [10]. This combination
of haemodynamic and renal effects appears beneﬁcial in
studies of experimental and human HF (heart failure)
[11–14], a state characterized by vasoconstriction and
ﬂuid/sodium retention. Accordingly, these peptides are
viewed as potential therapeutic candidates in this disease.
In 2006, Ogoshi et al. [15] identiﬁed the existence of
mammalian genes encoding AM5, and subsequent work
by this group demonstrated the highly conserved nature
of this peptide in mammals [16]. Bioactivity reported for
AM5 to date includes potent osmoregulatory effects in
ﬁsh (with a greater efﬁcacy than AM1) [17], whereas
intravenous administration in normal rats [16] and
sheep [18] produces signiﬁcant haemodynamic actions
including decreases in peripheral resistance and arterial
pressure together with increases in HR (heart rate) and
CO (cardiac output) with a potency comparable with
that seen with AM and AM2 [16,19,20]. Although these
ﬁndingspointtowardsaroleforAM5intheregulationof
thecardiovascularsystemandbodyﬂuidsinhealth,there
have been no studies investigating the effects of AM5 in
heart disease. Consequently, we investigated for the ﬁrst
time the integrated haemodynamic, endocrine and renal
effects of AM5 inHF usingan experimental ovine model.
MATERIALS AND METHODS
Surgical preparation
The study protocol was approved by the Animal
Ethics Committee of the University of Otago,
Christchurch. Eight Coopworth ewes (48–57 kg) were
instrumented as described previously [21] via a left
lateral thoracotomy under general anaesthesia [induced
by i.v. (intravenous) thiopentone (15 mg/kg of body
weight); maintained with 2.5% isoﬂurane, 2 l/min
nitrous oxide and 2 l/min oxygen) and using approved
peri-/post-operative analgesia [intercostal bupivacaine
0.5%/lignocaine 2%; i.v. carprofen (4 mg/kg of body
weight); i.v. buprenorphine (0.005–0.01 mg/kg of
body weight)]. Brieﬂy, two polyvinyl chloride catheters
were inserted in the left atrium for blood sampling and
measurement of LAP (left atrial pressure); a Konigsberg
pressure-tip transducer inserted in the aorta to record
MAP (mean arterial pressure) and into the apex of the
left ventricle to obtain maximum derivatives of pressure
over time [LV (left ventricular) dP/dt(max)] as an index
of contractility; an electromagnetic ﬂow probe placed
around the ascending aorta to measure CO; a Swan-
Ganz catheter inserted in the pulmonary artery for
administration of treatments; and a 7 French His-bundle
electrode stitched subepicardially to the wall of the left
ventricle for subsequent rapid pacing. A bladder catheter
was inserted per urethra for urine collections. Animals
recovered for 14 days before commencing the study
protocol. During the experiments the animals were held
in metabolic cages, fed on a standard laboratory diet
(500 g of sheep pellets and 250 g of chaff/day, containing
80 mmol sodium and 200 mmol potassium) and had free
access to water.
Study protocol
HF was induced by 7 days of rapid LV pacing at 225
beats/min [21,22] and maintained by continuous pacing
for the duration of the study. On days 8 and 10 of
pacing, each sheep received vehicle control (0.9% saline)
or porcine AM5 (Phoenix Pharmaceuticals) according
to a balanced random order design. AM5 was infused
at two incremental doses of 10 ng/min per kg of body
weight for 90 min [LD (low dose)] followed immediately
by 100 ng/min per kg of body weight for a further
90 min [HD (high dose)]. Both vehicle control and
AM5 infusions were administered in a total volume of
43 ml (0.9% saline) via the pulmonary artery catheter
commencing at 10:00 hours.
Using an online data acquisition system (PowerLab
Systems; AD Instruments), haemodynamic recordings
[MAP, LAP, CO, LV dP/dt (max) and CTPR (calculated
total peripheral resistance; CTPR=MAP/CO)] were
performed at 15 min intervals in the hour prior to
treatment (baseline) and at 15, 30, 45, 60 and 90 min
during both infusions and the post-infusion period. All
measurements were carried out with the sheep standing
quietly in the metabolic cage.
Blood samples were drawn fromthe left atrium30 min
and immediately pre-treatment (baseline) and at 30,
60 and 90 min during both infusions and the post-
infusion period. Samples were taken into EDTA tubes
on ice, centrifuged at 4◦C and stored at either −20◦C
or −80◦C before assay for the measurement of
cAMP, PRA (plasma renin activity), aldosterone, AVP
(argininevasopressin),cortisol,endothelin-1,ANP(atrial
natriuretic peptide), BNP (B-type natriuretic peptide),
adrenaline and noradrenaline [23]. For each hormone, all
samples from individual animals were measured in the
same assay to avoid inter-assay variability. Haematocrit
was measured with every blood sample taken. Samples
for analysis of plasma sodium, potassium and creatinine
concentrations were drawn into heparin tubes at 90 min
intervals starting immediately pre-treatment.
Waterintakeandurinecollectionsforthemeasurement
of volume and sodium, potassium, creatinine and cAMP
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excretion were made at 90 min intervals starting 90 min
before treatment.
Statistics
Results are expressed as means+ −S.E.M. Baseline
haemodynamic and hormonal values represent the mean
of measurements made within the hour immediately pre-
treatment.DifferencesbetweencontrolandAM5armsof
thestudy(treatment×timeinteractions)wereanalysedby
two-way repeated measures ANOVA. Signiﬁcance was
assumed when P<0.05. Where signiﬁcant differences
were identiﬁed by ANOVA, the level of signiﬁcance
at individual time points was determined by Fisher’s
protected least-signiﬁcant difference tests.
RESULTS
Similar to previous studies [21,22], rapid LV pacing at
225 beats/min for 7 days in the present study produced
the haemodynamic, endocrine and sodium-retaining
hallmarks of congestive HF, with reduced CO, MAP and
renal function, elevated LAP and peripheral resistance
and broad neurohormonal activation.
Compared with time-matched vehicle controls, infu-
sion of AM5 produced progressive and dose-dependent
increases in LV dP/dt(max) (LD +56 mmHg/s, HD
+152 mmHg/s) and CO (LD +0.83 l/min, HD +1.81
l/min),togetherwithsubstantialdecrementsinMAP(LD
−2.8mmHg,HD −8.4mmHg),LAP(LD −2.6mmHg,
HD −5.6 mmHg) and CTPR (LD −9.4 mmHg/min
per litre, HD −14.7 mmHg/min per litre; all P<0.001;
Figure 1). As seen in Figure 1, signiﬁcant changes were
observed during both the LD and HD infusions for
all haemodynamic measurements. Following termination
of AM5 administration, LV dP/dt(max), CO, LAP
and CTPR gradually returned to control levels over
the subsequent 30–90 min, whereas MAP rebounded
above time-matched control values during the 45–90 min
interval post-infusion. Haematocrit was signiﬁcantly
reduced by AM5 both during and after the infusion
period (P<0.001; Table 1).
PRA levels were unchanged during the LD AM5
infusion, but were signiﬁcantly elevated in response
to the HD (+1.77 nmol/h per litre; P<0.001), with
levels gradually returning to control concentrations over
the 90 min post-infusion period (Figure 2). In contrast,
plasma aldosterone levels were unaltered by either LD
or HD AM5 administration, but decreased signiﬁcantly
and progressively on cessation of treatment (P<0.01;
Figure2).Thesedifferencesinresponseswerereﬂectedin
marked reductions in the aldosterone/PRA ratio over the
HD and post-infusion periods (P<0.01; Table 1). Non-
dose-related trends for plasma cortisol to increase during
AM5 infusion did not achieve statistical signiﬁcance
(Figure 2).
Figure 1 Haemodynamic responses to intravenous infusions
of AM5 and vehicle control in eight sheep with HF
Values are means+ −S.E.M. Signiﬁcant differences between time-matched control
and AM5 data are shown by ∗P <0.05, †P <0.01 and ‡P <0.001.
Plasma cAMP levels fell initially during LD AM5 and
rose progressively during the HD infusion, before falling
again below time-matched control values post-infusion
(P<0.01; Figure 3). Despite clear reductions in LAP,
plasma ANP and BNP concentrations were maintained
duringAM5 infusions and showed a tendency to increase
post-infusion (both not signiﬁcant; Figure 3). Plasma
potassium concentrations declined relative to controls
over the HD and post-treatment periods (Table 1), while
plasma noradrenaline, adrenaline, AVP, endothelin-1,
sodiumandcreatininelevelswerenotsigniﬁcantlyaltered
by AM5 administration (Table 1).
AM5 induced signiﬁcant increases in urine output
(P<0.05) and urine sodium (P<0.01), potassium and
cAMP excretion (both P<0.05) during the HD infusion,
with increased output continuing during the post-
infusionperiod(Figure4).Creatinineexcretion(Figure4)
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Table 1 Effects of AM5 in sheep with HF
Values are means+ −S.E.M. responses to consecutive 90 min intravenous infusions of vehicle control and AM5 at 10 ng/min per kg of body weight (LD) and 100 ng/min
per kg of body weight (HD) in eight sheep with HF. Signiﬁcant differences are shown by ∗P <0.05, †P <0.01 and ‡P <0.001.
Variable Baseline (0 min) LD (90 min) HD (180 min) Post-infusion (270 min)
Haematocrit (%)
Control 27.2+ −0.9 26.4+ −0.9 25.6+ −0.8 25.6+ −0.9
AM5 27.0+ −1.1 25.6+ −1.0† 23.7+ −1.0‡ 22.4+ −1.0‡
Aldosterone/PRA ratio
Control 1447+ −571 1609+ −496 1975+ −867 2446+ −1025
AM5 1324+ −405 1552+ −457 627+ −385‡ 855+ −590‡
Plasma noradrenaline (pmol/l)
Control 6294+ −1829 12824+ −3752 8754+ −1778 11987+ −3664
AM5 4273+ −787 8421+ −1389 9032+ −2640 9910+ −2111
Plasma adrenaline (epinephrine) (pmol/l)
Control 401+ −73 584+ −171 475+ −106 482+ −89
AM5 338+ −56 497+ −92 484+ −113 403+ −76
Plasma vasopressin (pmol/l)
Control 2.01+ −0.14 2.46+ −0.47 1.99+ −0.26 2.28+ −0.29
AM5 2.17+ −0.49 2.19+ −0.44 2.25+ −0.45 1.46+ −0.21
Plasma endothelin-1 (pmol/l)
Control 4.89+ −0.73 5.27+ −0.80 5.42+ −0.98 5.03+ −0.77
AM5 5.20+ −0.80 5.33+ −0.70 4.86+ −0.68 5.29+ −0.70
Plasma sodium (mmol/l)
Control 144.4+ −1.1 144.9+ −1.2 144.5+ −0.8 144.3+ −0.5
AM5 143.6+ −0.6 143.9+ −0.4 143.4+ −0.3 143.1+ −0.7
Plasma potassium (mmol/l)
Control 4.25+ −0.19 4.33+ −0.19 4.35+ −0.19 4.36+ −0.20
AM5 4.09+ −0.12 4.23+ −0.14 4.04+ −0.15‡ 3.71+ −0.11‡
Plasma creatinine (μmol/l)
Control 81.3+ −2.3 80.3+ −2.3 79.5+ −1.6 81.1+ −2.9
AM5 84.9+ −3.8 85.3+ −3.6 82.3+ −3.3 81.8+ −3.9
Creatinine clearance (ml/min)
Control 50.2+ −5.4 47.8+ −7.1 49.1+ −6.9 46.5+ −7.2
AM5 54.0+ −8.9 62.7+ −5.5∗ 76.3+ −7.9‡ 56.2+ −11.7
Water intake (ml/1.5 h)
Control 450+ −75 496+ −106 169+ −74 250+ −73
AM5 591+ −167 294+ −116 309+ −81 205+ −59
and creatinine clearance (Table 1; both P<0.05) were
augmented by both doses of AM5. Drinking was
unchanged by AM5 (Table 1).
DISCUSSION
The present study investigated for the ﬁrst time the
integrated haemodynamic, endocrine and renal effects of
AM5 administration in experimental HF. AM5 induced
signiﬁcant and dose-dependent reductions in peripheral
resistance and arterial and atrial pressures, together with
increases in cardiac contractility and output. Although
AM5 activated PRA, plasma aldosterone levels were
suppressed and natriuretic peptide concentrations
were maintained despite the decline in LAP. AM5 also
enhanced renal function, producing signiﬁcant increases
in urine volume, sodium excretion and creatinine
clearance.
Members of the CGRP family are believed to exert
their biological effects in mammals principally through
interactionswithcombinationsoftheG-protein-coupled
CLR (calcitonin receptor-like receptor) and three
RAMPs (receptor activity-modifying proteins), resulting
in the generation of the intracellular second messenger,
cAMP [24]. Although plasma cAMP concentrations
tended to increase during the HD AM5 infusion in
the present study, levels did not rise signiﬁcantly above
control, and the LD infusion period was characterized
by clear-cut reductions in cAMP. This response differs
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Figure 2 PRA, aldosterone and cortisol responses to
intravenous infusions of AM5 and vehicle control in eight
sheep with HF
Values are means+ −S.E.M. Signiﬁcant differences between time-matched control
and AM5 data are shown by †P <0.01 and ‡P <0.001.
somewhat from that observed previously with identical
doses of AM [11] and AM2 [12] in sheep with HF,
where plasma cAMP levels were maintained during the
LD infusion and signiﬁcantly increased compared with
the control during the HD (Table 2). Our ﬁndings
with AM5 are consistent with the results from a
study by Takei et al. [16] that found the potency of
AM5 for cAMP accumulation (in COS-7 cells) with
any CLR–RAMP combination was much lower than
AM, although the cardiovascular effects of the two
peptides [i.v. and i.c.v (intracerebroventricular) in rats]
were comparable. This observation led the authors
to surmise that AM5 may have as yet unidentiﬁed
speciﬁc receptor(s) [and second messenger(s)] that differ
from CLR–RAMP complexes. However, the decrease in
circulating cAMP concentrations seen during LD AM5
in the present study probably reﬂects the haemodynamic
improvement noted during this period [25]. Despite
continued haemodynamic improvement during HD
AM5,cAMPlevelsrose,suggestingthatAM5didactivate
thissecondmessengerandmayindeedsignalviathesame
receptors as AM and AM2. Of note, AM5 administration
in normal sheep was associated with signiﬁcant increases
in circulating cAMP [18], albeit by amounts less than half
Figure 3 Plasma cAMP, ANP and BNP responses to
intravenous infusions of AM5 and vehicle control in eight
sheep with HF
Values are means+ −S.E.M. Signiﬁcant differences between time-matched control
and AM2 data are shown by ∗P <0.05 and †P <0.01.
that seen with equivalent doses of AM [19] and AM2 [20]
(Table 2).
Despite a possible reduced plasma cAMP response
to AM5 relative to AM and AM2, we found that the
haemodynamic effects of AM5 were largely comparable
in terms of magnitude and temporal proﬁle to that
produced by the other two AM peptides in this setting of
experimental HF [11,12] (Table 2). Similar comparative
potencies for all three AM peptides have previously been
reported in normal rats [16] and sheep [19] (Table 2).
Given these similarities, it is likely that the mechanisms
underlying these effects are analogous for the three
peptides. The hypotensive actions of AM and AM2 are
reported to be due to direct vasodilatory actions both
receptor mediated and via stimulation of nitric oxide [7],
andtheconcurrentfallsinMAPandperipheralresistance
seen with AM5 in the present study also suggest a direct
affectofthispeptideonarterialtone.Asimilarcorrelation
between falls in BP and CTPR was noted in normal
sheep with AM5 administration [18] (Table 2). In
comparison with AM, where reductions in MAP
persisted for 1 h post-infusion [11], MAP responses
were more transient with AM5 (the present study) and
AM2 [12] (absent after 30 min for both peptides). Takei
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Figure 4 Renal responses to intravenous infusions of AM5
and vehicle control in eight sheep with HF
Values are means+ −S.E.M. Signiﬁcant differences between time-matched control
and AM2 data are shown by ∗P <0.05, †P <0.01 and ‡P <0.001.
et al. [16] also observed a more short-lived BP effect of
AM5 relative to AM following i.c.v. administration of the
peptidesinrats.Thisdifferenceinthetimecoursesuggests
that the vasodilatory actions of AM5, like AM2, may
be mediated by CLR–RAMP complexes and/or other
unidentiﬁed receptors different from those mediating the
AM effect [26]. Clearly, additional studies are needed to
clarify this issue.
As observed previously in normal sheep [18], AM5
induced signiﬁcant and dose-dependent augmentation of
CO in the setting of HF. Although this effect is probably
attributable in part to the attendant reduction in cardiac
afterload (evidenced by falls in CTPR and MAP), it
is plausible that AM5 also exhibits positive inotropic
activity as the rise in CO was associated with prominent
increases in LV dP/dt(max). Similar increases in CO
and dP/dt(max) have been observed with AM and AM2
administration (Table 2) (in conjunction with enhanced
coronary artery perfusion ﬂow) [11,12,27], and both
peptides are reported to have direct inotropic actions in
isolated perfused rat hearts [8,9]. The AM5-induced rise
inCOinthepresentstudypresumablycontributedtothe
fallinLAP,althoughitisalsopossiblethatAM5possesses
venodilator actions as has been demonstrated for AM2
[28]. A decrease in blood volume cannot be implicated
as the signiﬁcant decline in LAP seen during the LD
AM5 infusion occurred well before the increase in urine
outputandinthefaceofafallinhaematocrit.Areduction
in haematocrit has been recorded previously following
AM5 administration in normal sheep [18] as well as
during AM2 infusion in HF animals [12], and suggests
a shift of ﬂuid from the extravascular to intravascular
compartment. The mechanisms underlying this effect are
yet to be determined for any of the AM peptides.
AM5 induced a signiﬁcant rise in PRA during the HD
infusion period in HF sheep, an effect also noted for
the peptide in normal animals [18] and similar to that
seen with AM and AM2 in experimental HF [11,12]
(Table 2). Although the activation of renin is likely to
be due, at least in part, to the decline in arterial pressure
seen during this period (via stimulation of afferent renal
arteriolar baroreceptors), it is also feasible that AM5 may
directly enhance renin release from the juxtaglomerular
cells in the kidney as previously demonstrated for AM
[29]. Although AM5 increased PRA [and presumably
AngII (angiotensin II)] levels in the present study, there
was no corresponding rise in plasma aldosterone. Indeed,
aldosterone concentrations were unaltered during HD
AM5 and signiﬁcantly reduced post-infusion (at which
time PRA was returning to control levels), resulting
in a considerable decline in the aldosterone/PRA ratio
and indicating inhibition of AngII-induced aldosterone
secretion. It is probable that AM5 has direct inhibitory
actions at the adrenal glomerulosa similar to those
demonstrated for the AM peptide [30] given the reports
of AM5 gene expression in the adrenal gland [16].
Contrary to our results in sheep with HF, AM5 induced
a rise in aldosterone in normal sheep [18] (Table 2).
However, this increment was minor in relation to the
concomitant increase in PRA with a resultant decrease
in the aldosterone/PRA ratio similar to that seen in
the present study in the setting of HF. The declines
in plasma potassium concentrations observed with AM5
administration in HF sheep may also have contributed to
the reduction in aldosterone.
Plasma concentrations of ANP and BNP were
maintained relative to control during AM5 infusion in
the present study despite clear falls in LAP and arterial
pressure (indicating reduced stimulus for secretion and
release of these peptides). Similar ANP/BNP responses
have been observed with AM and AM2 administration
in HF sheep [11,12], and suggest that the AM peptides
can either enhance secretion of ANP/BNP or alter
their clearance from the circulation to account for the
discrepancy between their sustained plasma levels and
the pronounced falls in LAP and MAP during the
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Table 2 Comparative effects of the AM peptides in normal and HF sheep
Summary and comparison of the major biological effects of AM, AM2 and AM5 in normal and HF sheep using an identical study design. Arrows indicate the maximum
responses to each peptide during the HD infusion period (100 ng/min per kg of body weight over 90 min) indicated by arrows (minor, moderate or large). ND,n o
data; −, no signiﬁcant change; right atrial pressure measured in normal animals, left atrial pressure measured in HF.
Data source AM AM2 AM5
Normal Charles et al. [19] Charles et al. [20] Charles et al. [18]
Variable HF Rademaker et al. [11] Rademaker et al. [12] The present study
HR (beats/min)
Normal ↑↑ ↑↑↑ ↑↑↑
HF ND ND ND
CO (l/min)
Normal ↑↑↑ ↑↑↑ ↑↑↑
HF ↑↑ ↑ ↑ ↑
dP/dt(max) (mmHg/s)
Normal ND ND ND
HF ND ↑↑↑ ↑↑↑
MAP (mmHg)
Normal ↓↓↓ ↓↓↓ ↓↓↓
HF ↓↓ ↓↓ ↓↓
Peripheral resistance (mmHg/min per litre)
Normal ↓↓ ↓↓ ↓↓
HF ↓↓↓ ↓↓↓ ↓↓↓
Right/left atrial pressure (mmHg)
Normal ↓− −
HF ↓↓ ↓↓ ↓↓
Plasma cAMP (pmol/l)
Normal ↑↑ ↑↑↑ ↑
HF ↑↑ ↑ −
PRA (nmol/l per h)
Normal ↑↑ ↑↑↑ ↑
HF ↑↑ ↑ ↑ ↑
Plasma aldosterone (pmol/l)
Normal ↑↑ ↑ ↑
HF ↓− −
Urine volume (ml/h)
Normal −−−
HF ↑↑ ↑↑ ↑↑
Urine sodium excretion (mmol/h)
Normal −−−
HF ↑↑↑ ↑↑↑ ↑↑↑
infusion period. While a possible direct stimulatory
effect of AM5 on natriuretic peptide secretion is
yet to be investigated, it is conceivable that AM5
modiﬁes some other regulatory mechanism of natriuretic
peptide production, such as AngII (indicated here by
increased PRA levels), which has been shown to directly
stimulate natriuretic peptide secretion from the heart
[31]. Alternatively, as has been shown for AM, AM5
may enhance the natriuretic peptide secretory responses
to AngII [32], endothelin-1 [33] and/or volume loading
[34], all of which are activated in, or characteristic
of, the HF state. Alternatively, AM5 may alter the
clearance of ANP/BNP. Although no information is as
yet available on the newly identiﬁed mammalian AM5
peptide, it appears likely that AM is degraded initially by
metalloproteases [35] and several in vivo studies provide
(indirect) evidence that NEP (neutral endopeptidase),
an enzyme signiﬁcantly involved in the clearance of
the natriuretic peptides [36], also contributes to the
degradation of AM, with plasma AM levels seen to
increase following NEP inhibition [37,38]. Thus possible
competition for the enzyme during AM5 administration
might result in the preservation of plasma ANP/BNP
concentrations observed in the present study. However,
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in vitro work suggests that NEP is not signiﬁcantly
involved in the metabolism of AM [35]. Clearly, further
investigationsarerequired,butwhateverthemechanisms,
the enhancement of natriuretic peptide levels in HF by
AM5 is favourable [36].
AM5 administration at the higher dose produced
signiﬁcant increments in urine output and urine sodium
and creatinine excretion in sheep with HF. Impressively,
these effects occurred in the face of substantial falls
in arterial pressure (and therefore presumably renal
perfusion pressure). These data contrast with ﬁndings
in normal sheep [18] and rats [16] where no signiﬁcant
renal effects of AM5 were observed. However, it should
be noted that in these studies in normal animals,
urine volume and sodium were maintained despite the
reductions in BP, suggesting a relative improvement
in renal function in normal health also. Although the
mechanisms underlying these renal actions of AM5 are
yet to be established, it is possible that an increase
in glomerular ﬁltration may have contributed in light
of the accompanying rise in creatinine clearance, as
well as the observed decrease in circulating aldosterone
levels. A similar enhancement of renal function has been
demonstratedpreviouslyfollowingidenticaldosesofAM
and AM2 in experimental ovine HF [11,12] (Table 2),
with modes of action reported to include reductions in
renal vascular resistance and increases in renal blood ﬂow
(via pre- and post-glomerular arteriolar vasodilation)
and glomerular ﬁltration rate, together with inhibition
of proximal and distal fractional sodium reabsorption
[37,39,40]. Similar direct actions of AM5 in the kidney
might also be a possibility given the signiﬁcant increase
in urine cAMP levels.
In summary, the present study is the ﬁrst to report
the effects of AM5 in HF using an experimental
ovine model and demonstrates that the peptide induces
signiﬁcant reductions in CTPR, MAP and LAP, together
with improvements in cardiac contractility and output.
AM5 activates PRA, but suppresses plasma aldosterone,
maintains natriuretic peptide concentrations despite falls
inLAPandenhancesrenalfunction.Ourﬁndingssuggest
that AM5, like AM and AM2, contributes to BP and
volume homoeostasis in HF. The spectrum of bioactivity
exhibited by AM5 in experimental HF which, at least
in the short term, are generally of a beneﬁcial nature,
raise the possibility that the peptide may have potential
as a therapeutic agent in human HF.
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